Medicament composition for treating pulmonary fibrosis

Abstract

The invention provides a medicament composition for treating pulmonary fibrosis. The medicament composition comprises the following active pharmaceutical ingredients by weight: 5-15 parts of ginseng, 5-15 parts of danshen root, 1-11 parts of angelica, 5-15 parts of manyflower solomonseal rhizome, 5-15 parts of perilla frutescens, 1-11 parts of brassica alba boiss, 1-11 parts of fructus aurantii immaturus and 5-15 parts of Japanese ardisia herb. The invention also provides a preparation method of the composition and application of the composition to preparing the medicaments for treating pulmonary fibrosis. The chemical fiber No.1 medicament composition provided by the invention has the effect of inhibiting proliferation of human embryo lung diploid fibroblasts (2BS), can be used for preparing the medicaments for treating pulmonary fibrosis, has obvious clinical effect, minimal side effect and good safety and provides a new choice for clinically treating pulmonary fibrosis.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a medicine composition for treating pulmonary fibrosis. Background technique [0002] Hu Zhuowei, a well-known authoritative scholar who has studied tissue and organ fibrosis for a long time, pointed out: "The latest research in the international medical community shows that all organs and tissues in the human body may have fibrosis. Many chronic diseases directly lead to fibrosis of organs and tissues. Fibrosis is a chronic disease. The root cause of long-term cure, which involves almost all organs and systems of the human body, is the main cause of disability and death in many diseases, and seriously threatens human health and life. Only by eradicating the root cause of chronic diseases - fibrosis, can chronic diseases be completely disintegrated. The dangers of stubborn diseases to human beings." [0003] Pulmonary fibrosis (PF) is the most representative, most typical and most frequ...

AI Technical Summary

Problems solved by technology

In terms of treatment, the current treatment of pulmonary fibrosis is limited to "stupid methods" such as non-specific anti-inflammation, immunosuppressants and glucocorticoids. Their common feature is the lack of specific treatment, and the extensive use of antibiotics and hormones is causing tissue and organ damage. An important cause of fibrosis, the latest research results are gradually revealing that long-term use of hormones and antibiotics to treat pulmonary fibrosis is much more serious than the fibrosis changes caused by the primary disease itself, and the problem of large toxic and side effects of chemical agents has not been resolved

Images